ESPOSITO, Roberto
 Distribuzione geografica
Continente #
NA - Nord America 9.504
EU - Europa 6.261
AS - Asia 1.365
Continente sconosciuto - Info sul continente non disponibili 26
SA - Sud America 16
AF - Africa 12
OC - Oceania 7
Totale 17.191
Nazione #
US - Stati Uniti d'America 9.461
GB - Regno Unito 2.386
IT - Italia 1.384
SE - Svezia 968
CN - Cina 605
DE - Germania 448
UA - Ucraina 405
TR - Turchia 371
FI - Finlandia 226
HK - Hong Kong 185
BG - Bulgaria 140
FR - Francia 113
IN - India 62
SG - Singapore 58
LT - Lituania 40
CA - Canada 38
IR - Iran 35
RU - Federazione Russa 35
IE - Irlanda 31
EU - Europa 24
BE - Belgio 20
NL - Olanda 18
ES - Italia 10
MY - Malesia 10
KR - Corea 9
PK - Pakistan 9
CH - Svizzera 8
AU - Australia 7
BR - Brasile 7
ID - Indonesia 7
ZA - Sudafrica 7
CO - Colombia 6
SI - Slovenia 6
JP - Giappone 4
PT - Portogallo 4
RS - Serbia 4
GR - Grecia 3
VN - Vietnam 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
CL - Cile 2
CU - Cuba 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
MG - Madagascar 2
NO - Norvegia 2
PA - Panama 2
PL - Polonia 2
RO - Romania 2
AM - Armenia 1
AR - Argentina 1
BD - Bangladesh 1
BT - Bhutan 1
BZ - Belize 1
CI - Costa d'Avorio 1
DK - Danimarca 1
IM - Isola di Man 1
JO - Giordania 1
PH - Filippine 1
SK - Slovacchia (Repubblica Slovacca) 1
SM - San Marino 1
Totale 17.191
Città #
Southend 2.066
Fairfield 1.105
Woodbridge 1.011
Chandler 918
Jacksonville 789
Houston 664
Ashburn 630
Dearborn 572
Nyköping 514
Wilmington 471
Ann Arbor 449
Cambridge 374
Seattle 373
Beijing 282
Izmir 245
Hong Kong 184
Princeton 147
Sofia 137
Eugene 135
San Diego 118
Milan 106
Des Moines 105
Modena 104
Helsinki 89
New York 82
Rome 70
Frankfurt am Main 53
Shanghai 53
Singapore 39
Naples 38
London 37
Philadelphia 34
Bremen 33
Nanjing 33
Boardman 30
Redwood City 29
Bologna 28
Dublin 27
Verona 27
Florence 22
San Mateo 22
Hefei 21
Norwalk 21
Augusta 18
Ottawa 18
Brussels 17
Falls Church 17
Parma 17
Kunming 16
Palermo 16
Bari 15
Catania 15
Los Angeles 15
Turin 15
Fremont 14
Grafing 14
Toronto 14
Guangzhou 13
Bangalore 12
Brescia 12
Auburn Hills 11
Saint Petersburg 11
Bergamo 10
Indiana 10
Jinan 10
Mashhad 10
Monmouth Junction 10
Mumbai 10
Hounslow 9
Kilburn 9
Paris 9
San Jose 9
Ardabil 8
Pescara 8
Piacenza 8
Pisa 8
Treviso 8
Chiswick 7
Jakarta 7
Leawood 7
Saint-martin-du-tertre 7
Amsterdam 6
Kish 6
Napoli 6
Padova 6
Renton 6
Rio Saliceto 6
Sassari 6
Washington 6
Borås 5
Cagliari 5
East London 5
Genoa 5
Legnano 5
Nanchang 5
Ningbo 5
Prescot 5
Ravenna 5
Shenyang 5
Vicenza 5
Totale 12.834
Nome #
Un raro caso di prostatite da Candida albicans, Candida krusei ed Enterococcus fecium 908
The human immunodeficiency virus (HIV) protease inhibitor indinavir directly affects the opportunistic fungal pathogen Cryptococcus neoformans 229
A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease. 228
Gli ascessi epatici nei pazienti sottoposi a trapianto ortotopico di fegato 220
Mitochondrial DNA Haplogroups and Highly Active Antiretroviral Therapy–Related Lipodystrophy 200
Nonalcoholic Fatty Liver Disease in HIV-Infected Patients Referred to a Metabolic Clinic: Prevalence, Characteristics, and Predictors 195
Gram-positive bloodstream infections in liver transplant recipients: incidence, risk factors, and impact on survival. 193
La clinica metabolica per il trattamento della lipodistrofia 189
Efficacy and safety of atazanavir in patients with end-stage liver disease. 188
Long-term psychometric outcomes of facial lipoatrophy therapy: forty-eight-week observational, nonrandomized study. 188
Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis 187
Brucellosis in a patient with end-stage liver disease undergoing liver transplantation: successful treatment with tigecycline. 180
Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital 179
Outcome, incidence, and timing of infectious complications in small bowel and multivisceral organ transplantation patients 177
Late presenters in an HIV surveillance system in Italy during the period 1992-2006. 177
MMP-7 promoter polymorphisms do not influence CD4+ recovery and changes in plasma viral load during antiretroviral therapy for HIV-1 infection. 177
Identification and characterization of an aspartyl protease from Cryptococcus neoformans 175
Congenital pyelectasis in children born from mothers on tenofovir containing therapy during pregnancy: report of two cases. 172
Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study. 172
Differential Dose Adjustments of Immunosuppressants after Resuming Boosted versus Unboosted HIV-Protease Inhibitors Postliver Transplant. 171
Facial lipohypertrophy in HIV-infected subjects who underwent autologous fat tissue transplantation. 170
Different sensitivity to apoptosis in cells of monocytic or lymphocytic origin chronically infected with human immunodeficiency virus type-1 166
Quantitation of CD95 and CD95L mRNA expression in chronic and acute HIV-1 infection by competitive RT-PCR 166
Role of therapeutic drug monitoring in a patient with human immunodeficiency virus infection and end-stage liver disease undergoing orthotopic liver transplantation 165
Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study 164
Genetic polymorphisms of Fas (CD95) and Fas ligand (CD178) influence the rise in CD4+ T cell count after antiretroviral therapy in drug-naive HIV-positive patients. 162
Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: An international observational study 161
Pathological fractures in AIDS patients with osteopenia and osteoporosis induced by antiretroviral therapy 160
MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients 160
Multidisciplinary approach to the treatment of metabolic and morphologic alterations of HIV-related lipodystrophy 160
Raltegravir and enfuvirtide as a “bridge” antiretroviral therapy in kidney-tranplanted patients with HIV infection receiving everolimus and low-dose cyclosporine: a case-control study 160
Fatal cytomegalovirus necrotising enteritis in a small bowel transplantation adult recipient with low pp65 antigenaemia levels 158
Deregulation of the CD95/CD95L system in lymphocytes from patients with primary acute HIV infection 154
Alendronate treatment for osteoporosis in patients infected with human immunodeficiency virus. 153
Features of 'CD4-exploders', HIV-positive patients with an optimal immune reconstitution after potent antiretroviral therapy 147
Applicazione della scala di valutazione, Functional indipendence Measure (FIM), per la valutazione dei programmi di riabilitazione per pazienti affetti da AIDS Dementia Complex ospiti di una casa alloggio 144
Artropodi vettori di agenti infettivi 143
Metabolic disorders induced by highly active antiretroviral therapy and their relationship with vascular remodeling of the brachial artery in a population of HIV-infected patients 143
Invasive pulmonary and cerebral aspergillosis in a patient with Weil's disease 141
Detectable HIV viral load is associated with metabolic syndrome. 141
Age-related comorbidities in people living with HIV 141
Prevalence of and risk factors for pubic lipoma development in HIV-infected persons 139
Un caso di tubercolosi post-trapianto ortotopico di fegato: limiti dell’impiego del quantiferon-TB gold nella diagnosi della infezione tubercolare latente ed attiva 139
Rituximab as treatment of posttransplant lymphoproliferative disorder in patients who underwent small bowel/multivisceral transplantation: Report of three cases 138
First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006). 136
Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function. 134
Psychometric evaluation of patients undergoing surgical treatment of HIV-related facial lipoatrophy 133
Body image is a major determinant of sexual dysfunction in stable HIV-infected women. 132
Outcome, incidence, and timing of infections in small bowel/multivisceral transplantation 131
Alendronate reduces bone turnover in HIV-associated Osteopenia and Osteoporosis 130
Improving the appropriateness of antibiotic prescription in hospitals: a pilot study assessing the effectiveness of an infectious diseases specialist's consultation programme 128
Morphologic alterations in HIV infected people with lipodystropy are associated with good adherence to HAART. 125
Autologous fat transfer for treating facial wasting in HIV body fat redistribution syndrome. 123
Autologous fat transfer for the treatment of HIV-related face lipoatrophy: 1-year follow-up 120
Pharmacokinetic interaction between amprenavir/ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation 119
Severity of lipodystrophy is associated with decreased health-related quality of life 118
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: The CARe study 118
Autologous fat transfer for the treatment of HIV-related face lipoatrophy: A long follow-up experience 117
Body Image is a major determinant of sexual dysfunction in stable HIV-infected women. 117
Association of serum vitamin D levels nd type 2 diabetes in HIV infection in the Modena cohort 117
Immunophenotype of HIV plus patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system 117
Psychometric evaluation in patients undergoing fillers injections for the treatment of HIV-related facial lipoatrophy: polylactic acid versus polyacrylamide 116
Autologous fat transfer for treating facial wasting in HIV-related lipodystrophy: experience of 53 treated patients 115
Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study 115
Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: The changes in opportunistic prophylaxis study 115
Prospective, partially randomized, 24-week study to compare the efficacy and durability of different surgical techniques and interventions for the treatment of HIV-related facial lipoatrophy 114
Dietary evaluation and metabolic alterations in HIV-related lipodystrophy 114
Statistical agreement between ATPIII, IDF, EGIR, AACE metabolic syndrome classifications in HIV-infected patients and association with lipodystrophy 114
Prevalence of secondary causes of osteoporosis among HIV infected individuals 113
CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 10(6) cells/I 112
The role of virological and immunological parameters on the diagnosis of metabolic syndrome in HIV-associated lipodystrophy 111
Posttransplant Mycobacterium tuberculosis disease following liver transplantation and the need for cautious evaluation of quantiferon TB GOLD results in the transplant setting: A case report 111
Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1 110
Bloodstream infections (BSIs) in Liver Transplant Recipients: Analisys at an Italian Tertiary-Care Hospital 110
Kinetics of CD4 cells after discontinuation of antiretroviral therapy in patients with virological failure and a CD4 cell count grater than 500 cells 110
Alendronate for the treatment of Osteoporosis in HIV-infected patients. 110
Candidemia nosocomiale: quattro anni di esperienza in un'ospedale universitario italiano 109
HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3. 107
La trasmissione verticale di HIV nell’era della HAART 106
Long lasting psycho-social benefits of polyacrylamide injections for the treatment of facial lipoatrophy 106
Does change of the liver change the metabolism? Assessment of atazanavir pharmacokinetic profile in 7 HIV-infected patients pre- and post-liver transplantation 105
Long-term follow-up of graft hypertrophy after autologous fat transfer for HIV-related face lipoatrophy (hamster syndrome 1 year later) 104
Studio caso-controllo sui fattori di rischio delle infezioni micotiche nei pazienti sottoposti a trapianto ortotopico di fegato (OLT) da donatore cadavere e da donatore vivente. 103
Assessment of 10-year probability of a major osteoporotic fracture in HIV-infected patients using FRAX® tool algorithms. 103
Does lipodistrophy affect quality of life? 103
Relapse of HIV-related buffalo hump after liposuction 102
È possibile un counselling HIV su internet? 101
CD4-Guided treatment interruptions: a new possibile therapeutic strategy 101
Validity of body image perception in women with HIV. 100
Different dose adjustments of immunosuppresants are necessary after initiating boosted or unboosted first protease inhibitors regimen post-liver transplantation 100
La casa alloggio: ospite, centro riabilitativo o entrambi? 96
Test di sensibilità antimicotica in vitro su isolati di Candida spp. da emocolture di pazienti ospedalizzati 96
GH response to GH-releasing hormone-arginine (GHRH+Arg) is impaired in women affected by human immunodeficiency virus (HIV)-related lipodystrophy 96
Autologous fat transfer for treating facial waisting in HIV body fat redistribution Syndrome 96
Pathological fractures in patients with osteopenia and osteoporosis induced by antiretroviral therapy 95
Declining morbidity and mortality in AIDS patients of an Italian nursing home 95
Body Image perception in HIV infected women with body fat redistribution. 93
Statistical agreement between metabolic syndrome ATP-III, IDF, EGIR and ACE classification in HIV-infected patients and association with body fat redistribution 93
Body image perception tests for lipodistrophy. 92
Mechanical and ultrasound-assisted liposuction for treating subcutaneous fat accumulations in HIV-related lipodystrophy: experience of 33 treated patients 92
Totale 14.379
Categoria #
all - tutte 63.533
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 63.533


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019603 0 0 0 0 0 0 0 0 0 0 0 603
2019/20203.629 322 142 147 254 367 521 577 511 313 95 193 187
2020/20212.617 236 78 182 255 404 230 213 288 133 280 195 123
2021/20222.286 31 374 189 246 53 85 118 177 220 134 367 292
2022/20232.854 300 261 229 240 316 467 46 288 333 55 166 153
2023/20241.688 111 139 122 176 283 151 149 199 52 60 104 142
Totale 17.396